NUTX logo

Nutex Health Inc. Stock Price

NasdaqCM:NUTX Community·US$912.4m Market Cap
  • 4 Narratives written by author
  • 1 Comments on narratives written by author
  • 45 Fair Values set on narratives written by author

NUTX Share Price Performance

US$132.59
14.93 (12.69%)
US$235.50
Fair Value
US$132.59
14.93 (12.69%)
43.7% undervalued intrinsic discount
US$235.50
Fair Value
Price US$132.59
AnalystConsensusTarget US$235.50
AnalystLowTarget US$175.00
mstock US$165.64

NUTX Community Narratives

·
Fair Value US$235.5 43.7% undervalued intrinsic discount

Expanding Micro Hospitals Will Serve Growing Demand Amid Regulatory Risks

0users have liked this narrative
0users have commented on this narrative
15users have followed this narrative
·
Fair Value US$175 24.2% undervalued intrinsic discount

No Surprises Act Risks Will Shrink Margins Yet Foster Adaptation

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Fair Value
·
Fair Value US$165.64 20.0% undervalued intrinsic discount

Nutex (NUTX) is undervalued

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
NUTX logo
Nutex Health

Nutex (NUTX) is undervalued

I believe earnings are forecast to increase. There is robust demand and robust earnings growth.Read more

View narrative
US$165.64
20.0% undervalued intrinsic discount
Fair Value
Revenue
19.3% p.a.
Profit Margin
10.76%
Future PE
8.2x
Price in 2030
US$231.4
US$235.5
43.7% undervalued intrinsic discount
Revenue
4.89% p.a.
Profit Margin
27.28%
Future PE
6.29x
Price in 2029
US$274.8
US$175
24.2% undervalued intrinsic discount
Revenue
5.25% p.a.
Profit Margin
21.15%
Future PE
7.95x
Price in 2029
US$132.56
US$300
55.8% undervalued intrinsic discount
Revenue
25.55% p.a.
Profit Margin
0.81%
Future PE
182.99x
Price in 2028
US$307.9

Trending Discussion

Updated Narratives

NUTX logo

Nutex (NUTX) is undervalued

Fair Value: US$165.64 20.0% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
NUTX logo

NUTX: Low EV EBITDA Multiple Will Support Future Upside Potential

Fair Value: US$235.5 43.7% undervalued intrinsic discount
15 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
NUTX logo

NUTX: Share Repurchases Will Support Future Margins And Upside Potential

Fair Value: US$175 24.2% undervalued intrinsic discount
5 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with proven track record.

2 Risks
4 Rewards

Nutex Health Inc. Key Details

US$880.0m

Revenue

US$434.9m

Cost of Revenue

US$445.1m

Gross Profit

US$348.7m

Other Expenses

US$96.4m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
14.01
50.58%
10.95%
9.3%
View Full Analysis

About NUTX

Founded
2011
Employees
1005
CEO
Thomas Vo
WebsiteView website
www.nutexhealth.com

Nutex Health Inc. operates as a healthcare services and operations company in the United States. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The Hospital segment develops and operates a network of micro hospitals, specialty hospitals, and hospital outpatient departments that offer healthcare services, including emergency room care, inpatient care, and behavioural health. It also provides imaging services, such as CT scan, X-ray, MRI, ultrasound, etc.; laboratory services; and onsite inpatient pharmacies. The PHM segment provides management, administrative, and other support services to its affiliated hospitals and physician groups by establishing and operating provider networks, such as independent physician associations (IPAs); and a cloud-based technology platform for IPAs. The Real Estate segment owns and leases land and hospital buildings. Nutex Health Inc. was founded in 2011 and is headquartered in Houston, Texas.

Recent NUTX News & Updates

Narrative Update Jun 04

NUTX: Low EV EBITDA Multiple Will Support Future Upside Potential

Analysts have raised their Nutex Health fair value estimate from $221.67 to $235.50, citing what they describe as a relatively low ~3x EV/EBITDA multiple and limited prior coverage of the stock as key reasons for the higher $235 price target. What's in the News No recent company specific news, periodical coverage, or key developments were identified in the provided sources for Nutex Health.
Narrative Update May 09

NUTX: Share Repurchases Will Support Future Margins And Upside Potential

Analysts now place Nutex Health's fair value at $175.00, up from $150.00, citing updated assumptions around revenue growth of 5.25%, a profit margin of 21.15%, a discount rate of 7.19% and a forward P/E of 7.95. What's in the News On March 5, 2026, the Board of Directors authorized a share buyback plan for Nutex Health.

Recent updates

No updates